|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
|
|
|
|||||||||||||||||||||||||
| Test | 05-MAY-2025 | Reference Range | Unit |
|---|---|---|---|
| Hemoglobin A1c/Hemoglobin.total in Blood | 6.0 | 4 - 6 | % |
| Glucose [Mass/volume] in Blood | 76.1 | 70 - 140 | mg/dL |
| Urea nitrogen [Mass/volume] in Blood | 18.9 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Blood | 0.9 | 0.9 - 1.3 | mg/dL |
| Calcium [Mass/volume] in Blood | 9.4 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Blood | 136.5 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Blood | 4.3 | 3.5 - 5 | mmol/L |
| Chloride [Moles/volume] in Blood | 104.3 | 98 - 110 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Blood | 20.4 L | 22 - 32 | mmol/L |
| Cholesterol [Mass/volume] in Serum or Plasma | 214.9 H | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 141.2 | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 159.3 H | 0 - 130 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 27.4 L | 40 - 60 | mg/dL |
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| The patient shows borderline elevated HbA1c, suggesting possible impaired glucose tolerance. Lipid profile reveals high total and LDL cholesterol, low HDL, and normal triglycerides, indicating increased cardiovascular risk. Mildly decreased total CO₂ may suggest a mild metabolic acidosis or compensated respiratory alkalosis. Renal function, electrolytes, and glucose are within normal limits. Recommend further cardiovascular risk assessment and consideration of lifestyle or pharmacological interventions. |